These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30706495)

  • 21. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Cavallin M; Kamath PS; Merli M; Fasolato S; Toniutto P; Salerno F; Bernardi M; Romanelli RG; Colletta C; Salinas F; Di Giacomo A; Ridola L; Fornasiere E; Caraceni P; Morando F; Piano S; Gatta A; Angeli P;
    Hepatology; 2015 Aug; 62(2):567-74. PubMed ID: 25644760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.
    Singh V; Kumar R; Nain CK; Singh B; Sharma AK
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):303-7. PubMed ID: 16460491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study.
    Moreau R; Asselah T; Condat B; de Kerguenec C; Pessione F; Bernard B; Poynard T; Binn M; Grangé JD; Valla D; Lebrec D
    Gut; 2002 Jan; 50(1):90-4. PubMed ID: 11772973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.
    Muñoz LE; Alcalá EG; Cordero P; Martínez MA; Vázquez NY; Galindo S; Mendoza E; Segura JJ
    Ann Hepatol; 2009; 8(3):207-11. PubMed ID: 19841499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Terlipressin and albumin combination treatment in hepatorenal syndrome.
    Danalioglu A; Cakaloglu Y; Karaca C; Aksoy N; Akyuz F; Ozdil S; Demir K; Besisik F; Boztas G; Mungan Z; Kaymakoglu S; Okten A
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccciii-cccv. PubMed ID: 15244209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reply to the letter to Editor on comparison of continuous versus intermittent infusions of terlipressin for the control of acute variceal bleeding in patients with portal hypertension: An open-label randomized controlled trial.
    Jha SK; Mishra M; Jha A; Dayal VM
    Indian J Gastroenterol; 2018 Nov; 37(6):565-566. PubMed ID: 30535917
    [No Abstract]   [Full Text] [Related]  

  • 27. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.
    Ortega R; Ginès P; Uriz J; Cárdenas A; Calahorra B; De Las Heras D; Guevara M; Bataller R; Jiménez W; Arroyo V; Rodés J
    Hepatology; 2002 Oct; 36(4 Pt 1):941-8. PubMed ID: 12297842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study.
    Fimiani B; Guardia DD; Puoti C; D'Adamo G; Cioffi O; Pagano A; Tagliamonte MR; Izzi A
    Eur J Intern Med; 2011 Dec; 22(6):587-90. PubMed ID: 22075285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?
    Piano S; Morando F; Fasolato S; Cavallin M; Boscato N; Boccagni P; Zanus G; Cillo U; Gatta A; Angeli P
    J Hepatol; 2011 Aug; 55(2):491-6. PubMed ID: 21334405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Response to Terlipressin and albumin is associated with improved outcome in patients with cirrhosis and hepatorenal syndrome].
    Nguyen-Tat M; Götz E; Scholz-Kreisel P; Ahrens J; Sivanathan V; Schattenberg J; Rey JW; Wörns MA; Galle PR; Marquardt JU
    Dtsch Med Wochenschr; 2015 Jan; 140(2):e21-6. PubMed ID: 25612289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
    Sanyal AJ; Boyer TD; Frederick RT; Wong F; Rossaro L; Araya V; Vargas HE; Reddy KR; Pappas SC; Teuber P; Escalante S; Jamil K
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1390-1402. PubMed ID: 28370090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of terlipressin and noradrenalin on cerebral perfusion, intracranial pressure and cerebral extracellular concentrations of lactate and pyruvate in patients with acute liver failure in need of inotropic support.
    Eefsen M; Dethloff T; Frederiksen HJ; Hauerberg J; Hansen BA; Larsen FS
    J Hepatol; 2007 Sep; 47(3):381-6. PubMed ID: 17599633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute kidney injury and hepatorenal syndrome in cirrhosis.
    Egerod Israelsen M; Gluud LL; Krag A
    J Gastroenterol Hepatol; 2015 Feb; 30(2):236-43. PubMed ID: 25160511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
    Krag A; Borup T; Møller S; Bendtsen F
    Adv Ther; 2008 Nov; 25(11):1105-40. PubMed ID: 19018483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Terlipressin for hepatorenal syndrome.
    Gluud LL; Christensen K; Christensen E; Krag A
    Cochrane Database Syst Rev; 2012 Sep; (9):CD005162. PubMed ID: 22972083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute kidney injury in cirrhosis: implications for liver transplantation.
    MacDonald AJ; Nadim MK; Durand F; Karvellas CJ
    Curr Opin Crit Care; 2019 Apr; 25(2):171-178. PubMed ID: 30676329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatorenal syndrome.
    Angeli P; Morando F; Cavallin M; Piano S
    Contrib Nephrol; 2011; 174():46-55. PubMed ID: 21921608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective effect of the vasopressin agonist terlipressin in a rat model of contrast-induced nephropathy.
    Ari E; Yilmaz Y; Kedrah AE; Alahdab Y; Cakalagaoglu F; Arikan H; Kocak H; Macunluoglu B; Atakan A; Kahveci A; Asicioglu E; Tuglular S; Ozener C
    Am J Nephrol; 2011; 33(3):269-76. PubMed ID: 21372562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome.
    Nazar A; Pereira GH; Guevara M; Martín-Llahi M; Pepin MN; Marinelli M; Solá E; Baccaro ME; Terra C; Arroyo V; Ginès P
    Hepatology; 2010 Jan; 51(1):219-26. PubMed ID: 19877168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early use of terlipressin in catecholamine-resistant shock improves cerebral perfusion pressure in severe traumatic brain injury.
    Salluh JI; Martins GA; Santino MS; Araújo LV; Freitas GG; Verdeal JC
    Acta Anaesthesiol Scand; 2007 Apr; 51(4):505-8. PubMed ID: 17378791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.